Also from this source

You just read:

Shield Therapeutics' ST10 Delivers Robust Results Meeting both Primary and Secondary Endpoints in the Pivotal AEGIS Phase 3 Programme for the Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease

News provided by

Shield Therapeutics

Jan 07, 2014, 02:00 EST